{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:16:17Z","timestamp":1786115777369,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00108-026-02111-7","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T11:04:00Z","timestamp":1776683040000},"page":"640-650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Versorgung von Patienten mit chronisch-obstruktiver Lungenerkrankung im klinischen Alltag","Management of patients with chronic obstructive pulmonary disease in routine clinical practice"],"prefix":"10.1007","volume":"67","author":[{"given":"Hendrik","family":"Pott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Schmeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"2111_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease - GOLD (2026) 2026 GOLD Report and Pocket Guide. https:\/\/goldcopd.org\/2026-gold-report-and-pocket-guide\/. Accessed 3.12.2025"},{"issue":"4","key":"2111_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/resp.14007","volume":"26","author":"P Lange","year":"2021","unstructured":"Lange\u00a0P, Ahmed\u00a0E, Lahmar\u00a0ZM, Martinez\u00a0FJ, Bourdin\u00a0A (2021) Natural history and mechanisms of COPD. Respirology 26(4):298\u2013321. https:\/\/doi.org\/10.1111\/resp.14007","journal-title":"Respirology"},{"key":"2111_CR3","doi-asserted-by":"publisher","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie COPD \u2013 Teilpublikation der Langfassung, 2.\u00a0Auflage. Version\u00a01. https:\/\/doi.org\/10.6101\/AZQ\/000477","DOI":"10.6101\/AZQ\/000477"},{"issue":"1","key":"2111_CR4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01499-2021","volume":"60","author":"S Stanojevic","year":"2022","unstructured":"Stanojevic\u00a0S, Kaminsky\u00a0DA, Miller\u00a0MR, Thompson\u00a0B, Aliverti\u00a0A, Barjaktarevic\u00a0I et\u00a0al (2022) ERS\/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir\u00a0J 60(1):2101499. https:\/\/doi.org\/10.1183\/13993003.01499-2021","journal-title":"Eur Respir J"},{"issue":"12","key":"2111_CR5","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1093\/aje\/kwq294","volume":"172","author":"S Sabia","year":"2010","unstructured":"Sabia\u00a0S, Shipley\u00a0M, Elbaz\u00a0A, Marmot\u00a0M, Kivimaki\u00a0M, Kauffmann\u00a0F et\u00a0al (2010) Why Does Lung Function Predict Mortality? Results From the Whitehall II Cohort Study. Am J Epidemiol 172(12):1415\u20131423. https:\/\/doi.org\/10.1093\/aje\/kwq294","journal-title":"Am J Epidemiol"},{"issue":"7059","key":"2111_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/bmj.313.7059.711","volume":"313","author":"DJ Hole","year":"1996","unstructured":"Hole\u00a0DJ, Watt\u00a0GC, Davey-Smith\u00a0G, Hart\u00a0CL, Gillis\u00a0CR, Hawthorne\u00a0VM (1996) Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 313(7059):711\u2013715. https:\/\/doi.org\/10.1136\/bmj.313.7059.711","journal-title":"BMJ"},{"issue":"4","key":"2111_CR7","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1164\/rccm.202008-3328PP","volume":"203","author":"MK Han","year":"2021","unstructured":"Han\u00a0MK, Agusti\u00a0A, Celli\u00a0BR, Criner\u00a0GJ, Halpin\u00a0DMG, Roche\u00a0N et\u00a0al (2021) From GOLD 0 to Pre-COPD. Am J Respir Crit Care Med 203(4):414\u2013423. https:\/\/doi.org\/10.1164\/rccm.202008-3328PP","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2111_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S2213-2600(21)00506-3","volume":"10","author":"IA Yang","year":"2022","unstructured":"Yang\u00a0IA, Jenkins\u00a0CR, Salvi\u00a0SS (2022) Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med 10(5):497\u2013511. https:\/\/doi.org\/10.1016\/S2213-2600(21)00506-3","journal-title":"Lancet Respir Med"},{"issue":"07","key":"2111_CR9","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1055\/a-1143-8186","volume":"74","author":"T Greulich","year":"2020","unstructured":"Greulich\u00a0T, F\u00e4hndrich\u00a0S, Clarenbach\u00a0C, Gleiber\u00a0W, Hautmann\u00a0H, Heine\u00a0R et\u00a0al (2020) Alpha-1-Antitrypsin-Mangel (AATM) \u2013 Ein Expertenstatement. Pneumologie 74(07):436\u2013442. https:\/\/doi.org\/10.1055\/a-1143-8186","journal-title":"Pneumologie"},{"issue":"1","key":"2111_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/crj.12180","volume":"10","author":"A Balkan","year":"2016","unstructured":"Balkan\u00a0A, Bulut\u00a0Y, Fuhrman\u00a0CR, Fisher\u00a0SN, Wilson\u00a0DO, Weissfeld\u00a0JL et\u00a0al (2016) COPD phenotypes in a lung cancer screening population. Clin Respir\u00a0J 10(1):48\u201353. https:\/\/doi.org\/10.1111\/crj.12180","journal-title":"Clin Respir J"},{"issue":"3","key":"2111_CR11","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.chest.2024.10.020","volume":"167","author":"H Yang","year":"2025","unstructured":"Yang\u00a0H, Yang\u00a0Y, Wang\u00a0F, Miao\u00a0C, Chen\u00a0Z, Zha\u00a0S et\u00a0al (2025) Clinical and Prognostic Differences in Mild to Moderate COPD With and Without Emphysema. CHEST 167(3):724\u2013735. https:\/\/doi.org\/10.1016\/j.chest.2024.10.020","journal-title":"CHEST"},{"issue":"2","key":"2111_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/thorax-2024-221928","volume":"80","author":"T Van Der Veer","year":"2025","unstructured":"Van Der Veer\u00a0T, Andrinopoulou\u00a0ER, Braunstahl\u00a0GJ, Charbonnier\u00a0JP, Kim\u00a0V, Latisenko\u00a0R et\u00a0al (2025) Association between automatic AI-based quantification of airway-occlusive mucus plugs and all-cause mortality in patients with COPD. Thorax 80(2):105\u2013108. https:\/\/doi.org\/10.1136\/thorax-2024-221928","journal-title":"Thorax"},{"issue":"3","key":"2111_CR13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01339-2020","volume":"57","author":"B Celli","year":"2021","unstructured":"Celli\u00a0B, Locantore\u00a0N, Yates\u00a0JC, Bakke\u00a0P, Calverley\u00a0PMA, Crim\u00a0C et\u00a0al (2021) Markers of disease activity in COPD: an 8\u2011year mortality study in the ECLIPSE cohort. Eur Respir\u00a0J 57(3):2001339. https:\/\/doi.org\/10.1183\/13993003.01339-2020","journal-title":"Eur Respir J"},{"issue":"2","key":"2111_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/resp.14843","volume":"30","author":"H Pott","year":"2025","unstructured":"Pott\u00a0H, Weckler\u00a0B, Gaffron\u00a0S, Martin\u00a0R, Maier\u00a0D, Alter\u00a0P et\u00a0al (2025) Diffusion capacity and static hyperinflation as markers of disease progression predict 3\u2011year mortality in COPD: Results from COSYCONET. Respirol Carlton Vic 30(2):134\u2013146. https:\/\/doi.org\/10.1111\/resp.14843","journal-title":"Respirol Carlton Vic"},{"key":"2111_CR15","unstructured":"S3-Leitlinie \u201cRauchen und Tabakabh\u00e4ngigkeit: Screening, Diagnostik und Behandlung\u201d."},{"key":"2111_CR16","unstructured":"Infoblatt Rauchfrei Leben, Flyer zur Tabakentw\u00f6hnung_2025, Datum des Zugriffs 27.2.026, URL: https:\/\/www.atemwegsliga.de\/files\/eigene-dateien\/informationsmaterial\/Info-Weitere\/Flyer%20zur%20Tabakentw%C3%B6hnung_2025.pdf"},{"key":"2111_CR17","doi-asserted-by":"crossref","unstructured":"Osadnik CR, Brighton LJ, Burtin C, Cesari M, Lahousse L, Man WDC, et\u00a0al. European Respiratory Society statement on frailty in adults with chronic lung disease. Eur Respir J;62(2). https:\/\/doi.org\/10.1183\/13993003.00442-2023","DOI":"10.1183\/13993003.00442-2023"},{"issue":"04","key":"2111_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1055\/s-0043-125031","volume":"72","author":"C Vogelmeier","year":"2018","unstructured":"Vogelmeier\u00a0C, Buhl\u00a0R, Burghuber\u00a0O, Cri\u00e9e\u00a0CP, Ewig\u00a0S, Godnic-Cvar\u00a0J et\u00a0al (2018) Leitlinie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie 72(04):253\u2013308. https:\/\/doi.org\/10.1055\/s-0043-125031","journal-title":"Pneumologie"},{"issue":"1","key":"2111_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/418092","volume":"2014","author":"E Pompeo","year":"2014","unstructured":"Pompeo\u00a0E (2014) Lung Volume Reduction Surgery for Emphysema Treatment: State-of-the-Art and Perspectives. Int Sch Res Not 2014(1):418092. https:\/\/doi.org\/10.1155\/2014\/418092","journal-title":"Int Sch Res Not"},{"key":"2111_CR20","doi-asserted-by":"crossref","unstructured":"Michel S, Schneider C, Ius F, Welte T, Gottlieb J, Kneidinger N. Lung transplantation \u2014 indications, follow-up care and long-term results. Dtsch \u00c4rztebl Int. https:\/\/doi.org\/10.3238\/arztebl.m2024.0232","DOI":"10.3238\/arztebl.m2024.0232"},{"key":"2111_CR21","unstructured":"Deutsche Gesellschaft f\u00fcr Allgemeinmedizin und Familienmedizin (DEGAM), Berlin, Deutsche Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin (DGP), Berlin. S2k-Leitlinie Klimabewusste Verordnung von Inhalativa. AWMF-Register-Nr. 053-059."},{"issue":"11","key":"2111_CR22","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1164\/rccm.202108-1819PP","volume":"204","author":"BR Celli","year":"2021","unstructured":"Celli\u00a0BR, Fabbri\u00a0LM, Aaron\u00a0SD, Agusti\u00a0A, Brook\u00a0R, Criner\u00a0GJ et\u00a0al (2021) An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. Am J Respir Crit Care Med 204(11):1251\u20131258. https:\/\/doi.org\/10.1164\/rccm.202108-1819PP","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2111_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S2213-2600(25)00362-5","volume":"14","author":"HWW Aung","year":"2026","unstructured":"Aung\u00a0HWW, Vermeersch\u00a0K, McAuley\u00a0HJC, Ramakrishnan\u00a0S, Abdo\u00a0M, Beersaerts\u00a0A et\u00a0al (2026) Multidimensional prognostic risk stratification of COPD exacerbations: the baseline, acuity, and trigger (BAt) model. Lancet Respir Med 14(2):174\u2013186. https:\/\/doi.org\/10.1016\/S2213-2600(25)00362-5","journal-title":"Lancet Respir Med"},{"key":"2111_CR24","doi-asserted-by":"crossref","unstructured":"Janssen DJA, Bajwah S, Boon MH, Coleman C, Currow DC, Devillers A, et\u00a0al. European Respiratory Society clinical practice guideline: palliative care for people with COPD or interstitial lung disease. Eur Respir J;62(2). https:\/\/doi.org\/10.1183\/13993003.02014-2022","DOI":"10.1183\/13993003.02014-2022"}],"updated-by":[{"DOI":"10.1007\/s00108-026-02173-7","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000}}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02111-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02111-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02111-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T05:39:06Z","timestamp":1785994746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02111-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2111"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02111-7","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: Tabelle 2 und 3 wurden korrigiert.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00108-026-02173-7","URL":"https:\/\/doi.org\/10.1007\/s00108-026-02173-7","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.\u00a0Pott\n                      : A.\u00a0Finanzielle Interessen: AstraZeneca: Kongressteilnahme. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Assistenzarzt und Clinician Scientist, Klinik f\u00fcr Pneumologie, Intensiv- und Schlafmedizin, Phillips-Universit\u00e4t Marburg (UMR), Universit\u00e4tsklinikum Gie\u00dfen und Marburg (UKGM), Standort Marburg, Baldingerstra\u00dfe, 35043 Marburg | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin (DGP), European Respiratory Society (ERS), Deutsche Gesellschaft f\u00fcr Innere Medizin (DGIM), Deutsche Lungenstiftung (DLS).\n                      B.\u00a0Schmeck\n                      : A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung an die Universit\u00e4t Marburg von: Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt (BMFTR), Bundesministerium f\u00fcr Gesundheit (BMG), der Firma CSL Behring.\u00a0\u2013 Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Chiesi, INSMED. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Universit\u00e4tsprofessor, Universit\u00e4t Marburg, Sektionsleiter, UKGM, Universit\u00e4tsklinikum Marburg | Mitgliedschaften: DGP, ERS, DGIM, Marburger Bund.\n                      P.\u00a0Alter\n                      : A.\u00a0Finanzielle Interessen: \u201eUnrestricted grants\u201c f\u00fcr COSYCONET von GlaxoSmithKline GmbH & Co KG, Chiesi GmbH, AstraZeneca GmbH, Sanofi Aventis GmbH.\u00a0\u2013 Sanofi Aventis Deutschland GmbH: Advisory Board, StreamedUp GmbH: Honorar, Sanofi Aventis Deutschland GmbH: Kongressteilnahme, Boehringer Ingelheim GmbH: Kongressteilnahme. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Stellvertretender Direktor & leitender Oberarzt, Klinik f\u00fcr Pneumologie, Intensiv- und Schlafmedizin, Philipps-Universit\u00e4t Marburg (UMR), Universit\u00e4tsklinikum Gie\u00dfen und Marburg GmbH, Standort Marburg, Baldingerstra\u00dfe, 35043 Marburg | Mitgliedschaften: DGP, ERS, Deutsche Gesellschaft f\u00fcr Kardiologie \u2013 Herz- und Kreislaufforschung (DGK), European Society of Cardiology (ESC), Fellow of the European Society of Cardiology (FESC), DGIM.\n                      G.\u00a0Rohde\n                      : A.\u00a0Finanzielle Interessen: F\u00f6rderung der BUCOSS- und der BUCOSS-Hosp-Studien durch Firma GSK; Unterst\u00fctzung Aufbau NTM Register durch Firma Insmed.\u00a0\u2013 Prof. Rohde erhielt Honorare von AstraZeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Sanofi, Solvay, Takeda, Novartis, Pfizer und Vertex f\u00fcr Vortr\u00e4ge. \u2013\u00a0Prof. Rohde erhielt Honorare von AstraZeneca, Atriva, Boehringer Ingelheim, GSK, Insmed, Johnson & Johnson, MSD, Sanofi, Novartis und Pfizer als Berater.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Direktor der Klinik f\u00fcr Pneumologie, Intensiv- und Schlafmedizin des Universit\u00e4tsklinikums Marburg | Vorstandsvorsitzender der CAPNETZ Stiftung.","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}